Publication Name	World Journal of Clinical Cases
Manuscript ID	12735
Country	Italy

Received	2014-07-24 08:57
Peer-Review Started	2014-07-24 16:29
To Make the First Decision	2014-08-14 14:57
Return for Revision	2014-08-15 11:29
Revised	2014-09-01 21:16
Second Decision	2014-10-16 15:07
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2014-10-16 15:41
Articles in Press	2014-10-16 15:42
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2014-12-10 19:14
Publish the Manuscript Online	2014-12-18 14:44

ISSN	2307-8960 (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Oncology
Manuscript Type	Minireviews
Article Title	Role of MGMT as biomarker in colorectal cancer
Manuscript Source	Invited Manuscript
All Author List	Alessandro Inno, Giuseppe Fanetti, Maria Di Bartolomeo, Stefania Gori, Claudia Maggi, Massimo Cirillo, Roberto Iacovelli, Federico Nichetti, Antonia Martinetti, Filippo de Braud, Ilaria Bossi and Filippo Pietrantonio
Funding Agency and Grant Number
Corresponding Author	Filippo Pietrantonio, MD, Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian, 20100 Milan, Italy. filippo.pietrantonio@istitutotumori.mi.it
Key Words	Colorectal cancer; O6-methylguanine DNA methyltransferase; Temozolomide; Dacarbazine; Biomarker
Core Tip	O6-methylguanine DNA methyltransferase (MGMT) methylation is involved in colorectal carcinogenesis and represents a predictive biomarker for alkylating agents in metastatic colorectal cancer. In fact, patients with chemorefractory metastatic colorectal cancer with MGMT methylation derived promising response from treatment with dacarbazine or temozolomide, and ongoing research is investigating the efficacy of temozolomide in combination with other chemotherapy drugs for MGMT-methylated colorectal cancer. Future challenges include the combination with biologic drugs and the research for additional biomarkers.
Publish Date	2014-12-18 14:44
Citation	Inno A, Fanetti G, Di Bartolomeo M, Gori S, Maggi C, Cirillo M, Iacovelli R, Nichetti F, Martinetti A, de Braud F, Bossi I, Pietrantonio F. Role of MGMT as biomarker in colorectal cancer. World J Clin Cases 2014; 2(12): 835-839
URL	http://www.wjgnet.com/2307-8960/full/v2/i12/835.htm
DOI	http://dx.doi.org/10.12998/wjcc.v2.i12.835

Full Article (PDF)	WJCC-2-835.pdf
Full Article (Word)	WJCC-2-835.doc
Manuscript File	12735-Review.docx
Answering Reviewers	12735-Answering reviewers.pdf
Copyright License Agreement	12735-Copyright assignment.pdf
Peer-review Report	12735-Peer review(s).pdf
Scientific Misconduct Check	12735-CrossCheck.jpg
Scientific Editor Work List	12735-Scientific editor work list.pdf